Arena Pharmaceuticals Inc (ARNA)
$99.99
$0.00 (0.00%)As on 14-Mar-2022 09:30EDT
Market cap
$6,165 Mln
Revenue (TTM)
$-3 Mln
P/E Ratio
--
P/B Ratio
9.2
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-616 Mln
-
ROE
-0.7 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
3.5
-
Debt to Equity
0.1
-
Book Value
$11
-
EPS
$-10.1
-
Face value
--
-
Shares outstanding
61,659,400
10 Years Aggregate
CFO
$-668.17 Mln
EBITDA
$-936.14 Mln
Net Profit
$-1,040.33 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Arena Pharmaceuticals Inc (ARNA)
| 7.6 | 6.6 | 11.0 | 29.7 | 29.9 | 47.3 | 18.6 |
|
BSE Sensex*
| -10.4 | -1.0 | -7.8 | -7.7 | 6.7 | 8.3 | 11.1 |
|
Company
|
2021
|
2020
|
2019
|
2018
|
2017
|
2016
|
2015
|
|---|---|---|---|---|---|---|---|
|
Arena Pharmaceuticals Inc (ARNA)
| 21.0 | 69.2 | 16.6 | 14.6 | 139.2 | -25.3 | -45.2 |
|
BSE Sensex
| 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 | -5.0 |
|
BSE Sensex
| 22.0 | 15.8 | 14.4 | 5.9 | 27.9 | 1.9 | -5.0 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Arena Pharmaceuticals Inc (ARNA)
|
100.0 | 6,165.3 | 0.1 | -616.4 | 16,017.4 | -70.3 | -- | 9.2 |
| 18.7 | 1,075.9 | 0.0 | -167.9 | -- | -128.7 | -- | 5.2 | |
| 26.7 | 16,496.4 | 8,837.9 | 2,614.3 | 36.5 | 45.7 | 20.5 | 2.9 | |
| 11.3 | 2,061.7 | 550.0 | 458.1 | -3.3 | 45.9 | 4.5 | 1.7 | |
| 5.3 | 1,059.4 | 4.5 | -340.2 | -518.6 | 501.4 | -- | 2.1 | |
| 14.7 | 1,965.1 | 17.2 | -102.1 | -363.1 | -19 | -- | 3.4 | |
| 13.7 | 889.9 | 106,763.2 | 5,307.0 | 5.8 | 2147 | 66.3 | 3.3 | |
| 3.2 | 536.4 | 4.0 | -198.4 | -5,037.7 | -166.3 | -- | 7.0 | |
| 18.3 | 419.9 | 4.7 | -109.7 | -- | -30.2 | -- | 1.4 | |
| 18.4 | 2,090.9 | 453.3 | -178.1 | -38.4 | -25.1 | -- | 3.2 |
Shareholding Pattern
View DetailsAbout Arena Pharmaceuticals Inc (ARNA)
Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. The company's investigational clinical programs include Etrasimod (APD334) that is in Phase... III clinical trial for ulcerative colitis, Phase IIb/III clinical trial for Crohn's disease, Phase II clinical trial for alopecia areata, Phase III clinical trial for atopic dermatitis, and Phase IIb clinical trial for eosinophilic esophagitis; Olorinab (APD371), which is in Phase IIb clinical trial for the treatment of abdominal pain associated with irritable bowel syndrome; APD418 that is in Phase II clinical trial for acute heart failure; and Temanogrel for coronary microvascular obstruction that is in Phase II clinical trial. It also develops ralinepag (APD811), which is in Phase III clinical trial for pulmonary arterial hypertension. The company has collaboration agreements with United Therapeutics Corporation; Everest Medicines Limited; Eisai Co., Ltd. and Eisai Inc.; Boehringer Ingelheim International GmbH; Beacon Discovery, Inc.; and Aristea Therapeutics, Inc. Arena Pharmaceuticals, Inc. was incorporated in 1997 and is based in Park City, Utah. As of March 11, 2022, Arena Pharmaceuticals, Inc. operates as a subsidiary of Pfizer Inc. Read more
-
Pres & CEO
Mr. Amit D. Munshi M.B.A.
-
Pres & CEO
Mr. Amit D. Munshi M.B.A.
-
Headquarters
Park City, UT
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Arena Pharmaceuticals Inc (ARNA)
What is the current share price of Arena Pharmaceuticals Inc (ARNA) Today?
The share price of Arena Pharmaceuticals Inc (ARNA) is $99.99 (NASDAQ) as of 14-Mar-2022 09:30 EDT. Arena Pharmaceuticals Inc (ARNA) has given a return of 29.86% in the last 3 years.
What is the current PB & PE ratio of Arena Pharmaceuticals Inc (ARNA)?
Since, TTM earnings of Arena Pharmaceuticals Inc (ARNA) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2021
|
-9.20
|
8.42
|
|
2020
|
-10.44
|
3.91
|
|
2019
|
5.94
|
2.20
|
|
2018
|
-62.27
|
3.02
|
|
2017
|
-12.26
|
5.41
|
What is the 52 Week High and Low of Arena Pharmaceuticals Inc (ARNA)?
The 52-week high and low of Arena Pharmaceuticals Inc (ARNA) are Rs -- and Rs -- as of 28-May-2026.
What is the market cap of Arena Pharmaceuticals Inc (ARNA)?
Arena Pharmaceuticals Inc (ARNA) has a market capitalisation of $ 6,165 Mln as on 14-Mar-2022. As per SEBI classification, it is a company.
Should I invest in Arena Pharmaceuticals Inc (ARNA)?
Before investing in Arena Pharmaceuticals Inc (ARNA), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.